{
    "info": {
        "nct_id": "NCT02844816",
        "official_title": "Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer",
        "inclusion_criteria": "* Patients must have histologically proven, recurrent, non-muscle invasive urothelial carcinoma of the bladder within 60 days prior to registration; the carcinoma must be stage T1 high-grade, stage CIS, or stage Ta high-grade\n* Patients with mixed urothelial carcinoma and a glandular and/or squamous component will be eligible for the trial, but the presence of other histologic variants, pure adenocarcinoma, or pure squamous cell carcinoma, or pure squamous carcinoma in situ will make a patient ineligible\n* Patients must have had all visible tumor resected completely within 60 days prior to registration; CIS disease is not expected to be completely excised; all patients must have tumor tissue from the histologic diagnosis of recurrence available for central pathology review submission; failure to submit these materials will make the patient ineligible for this study\n* Patients must have had cystoscopy confirming no visible papillary tumor within 21 days prior to registration; (CIS disease is not expected to have been completely excised); if the transurethral resection of bladder tumor (TURBT) or bladder biopsy falls within 21 days of registration it will fulfill this criterion\n* Patients must have had urine cytology within 21 days prior to registration; cytology for patients with CIS component is not expected to be negative for malignant cells; if the cytology for male patients with only Ta/T1 disease in the absence of CIS is positive for malignant cells, patient must have had a biopsy of the prostatic urethra within the previous six months\n* All patients with T1 urothelial carcinoma at study entry must undergo re-TURBT within 60 days prior to registration, and must have evidence of uninvolved muscularis propria in the pathologic specimen from either the first or the second TURBT; tissue from the re-resection must be submitted for central review in addition to the tissue from the first TURBT; the TURBT that identified the recurrent T1 disease may have taken place more than 60 days prior to registration but not more than 120 days; patients with high grade Ta or CIS do not require a re-TURBT, but if this is performed at the discretion of the treating physician, the second TURBT must be within 60 days of registration; there is no requirement for muscularis propria in the specimen of Ta/CIS patients, but the tissue from the first and second TURBTs must be submitted for central review; if a patient with Ta/T1 disease undergoes repeat TURBT, the patient will be stratified as having CIS if there is CIS on either TURBT\n* Patients must not have had urothelial carcinoma in the prostatic urethra within the previous 24 months or muscle invasive urothelial carcinoma of the bladder at any time; patients with prior urothelial carcinoma in the upper urinary tract within the previous 24 months will only be eligible if they had =< T1 carcinoma and were treated with nephroureterectomy; patients must have a computed tomography (CT) or magnetic resonance imaging (MRI) (including CT-intravenous pyelogram [IVP], CT-urogram or MR-urogram) of the abdomen and pelvis to rule out upper tract malignancy and intra-abdominal metastases within 90 days prior to registration; if a patient cannot tolerate intravenous contrast, a retrograde pyelogram should be performed within 90 days prior to registration\n* Patients must be deemed unfit for radical cystectomy by the treating physician, or the patient must refuse radical cystectomy, which is considered standard of care for these patients; the reason for patients not to undergo cystectomy will be clearly documented\n* Patients must be BCG-unresponsive; a patient is BCG-unresponsive if they meet one or more of the following criteria:\n\n  * Patient has persistent or recurrent high-grade Ta/CIS urothelial carcinoma after completing therapy with at least induction BCG (>= 5 doses) and first round maintenance (>= 2 doses) or second induction BCG (>= 2 doses); both rounds of BCG must have been administered within a 12 month period; these patients must have either had high-grade Ta tumors and did not achieve a disease-free state for more than 6 months following last dose of BCG, or they had CIS and did not achieve a CR; S1605 registration must occur within 9 months of the last dose of BCG\n\n    * If a patient does not meet these criteria only because the last dose of BCG was more than 9 months ago, the patient may become eligible if he/she shows histologically proven high-grade recurrence after an additional round of induction or maintenance BCG (>= 3 doses) within 9 months prior to registration\n  * Patient has persistent or recurrent high grade T1 urothelial carcinoma after completing therapy with at least induction BCG (>= 5 doses); patients with recurrent high grade T1 urothelial carcinoma after additional rounds of BCG will also be eligible, but one round of maintenance therapy or a second induction is not a pre-requisite for these patients. Trial registration must occur within 9 months of the last dose of BCG\n\n    * If a patient does not meet these criteria only because the last dose of BCG was more than 9 months ago, the patient may become eligible if he/she shows histologically proven high grade recurrence after an additional round of induction or maintenance BCG (>= 3 doses) within 9 months prior to registration\n  * Patient achieves disease-free state at 6 month time point (i.e., complete response; presence of only low-grade tumor at this timepoint is still considered complete response) after induction and maintenance (or second round of induction) BCG but later experiences a high-grade Ta/T1 recurrence (with or without concomitant CIS) within 6 months after the last dose of BCG or recurrent CIS (in absence of concomitant Ta/T1 tumor) within 12 months after the last BCG dose; the time of eligibility is measured from the last dose of BCG to the time of disease recurrence; the patient must be registered on the trial within 60 days of this recurrence, or within 60 days of a re-TURBT if indicated\n* All adverse events associated with any prior surgery and intravesical therapy must have resolved to grade =< 2 prior to registration\n* Absolute neutrophil count (ANC) >= 1,500 microliter (mcL) (within 42 days prior to registration)\n* Platelets >= 100,000/mcL (within 42 days prior to registration)\n* Hemoglobin >= 9 g/dL (within 42 days prior to registration)\n* Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (except Gilbert's syndrome, who must have a total bilirubin < 3.0 mg/dL) (within 42 days prior to registration)\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2 x IULN (within 42 days prior to registration)\n* Serum creatinine =< 1.5 ULN OR measured or calculated creatinine clearance >= 30 mL/min (within 42 days prior to registration)\n* Patients must have Zubrod performance status =< 2\n* Patients must have a baseline electrocardiograph (ECG) performed within 42 days prior to registration\n* Patients positive for human immunodeficiency virus (HIV) are eligible only if they have all of the following:\n\n  * A stable regimen of highly active anti-retroviral therapy (HAART)\n  * No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\n  * A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests\n* No other prior malignancy is allowed except, for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years\n* Patients must be offered the opportunity to participate in specimen banking for future studies, to include translational medicine studies\n* Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines\n* As a part of the oncology patient enrollment network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Patients must not have had prior systemic chemotherapy for bladder cancer or systemic immunotherapy, including, but not limited to interferon alfa-2b, high dose interleukin 2 (IL-2), pegylated interferon (PEG-IFN), PD-1, anti-PD-L1, intra-tumoral; patients must not have had vaccine therapies within 6 weeks prior to registration; patients must not have received or be planning to receive any of the prohibited therapies during protocol treatment; prior intravesical administration of chemotherapy, interferon, Vicinium (VB4-485), BC-819 or Instiladrin (rAd-interferon-alpha/Syn3) is allowed if all other criteria are met and the last administration was >= 30 days before registration\n* Patients must not be planning to receive concomitant other biologic therapy, radiation therapy, intravesical chemotherapy, surgery, or other anti-cancer therapy while on this protocol\n* Patients must not have received any prior radiation to the bladder for bladder cancer\n* Patients must not have received treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 4 weeks prior to registration; exceptions: (1) patients may have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea); (2) the use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed\n* Patients must not have received a live, attenuated vaccine within 4 weeks before registration or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab\n\n  * Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the study\n* Patients must not require treatment with a RANKL inhibitor (e.g. denosumab) who cannot discontinue it before treatment with atezolizumab\n* Patient must not have history of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis\n* Patients must not have an active infection requiring oral or IV antibiotics within 14 days prior to registration; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible\n* Patients must not have severe infections within 28 days prior to registration, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia\n* Patients must not have active autoimmune disease that has required systemic treatment in past two years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment; autoimmune diseases include, but are not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis\n* Patients must not have undergone prior allogeneic bone marrow transplantation or prior solid organ transplantation\n* Patient must not have active tuberculosis\n* Patients must not have active hepatitis B (chronic or acute) or active hepatitis C infection\n\n  * Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible\n  * Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA\n* Patients must not be pregnant or nursing due to the potential teratogenic side effects of the protocol treatment; administration of atezolizumab may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of study agent; a woman is considered to be of \"reproductive potential\" if she has had menses at any time in the preceding 12 consecutive months; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n* Due to the potential drug reaction with atezolizumab, patients must not be known to be allergic to Chinese hamster egg or ovaries",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Hemoglobin >= 9 g/dL (within 42 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin >= 9 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients positive for human immunodeficiency virus (HIV) are eligible only if they have all of the following:",
            "criterions": [
                {
                    "exact_snippets": "Patients positive for human immunodeficiency virus (HIV)",
                    "criterion": "HIV status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has persistent or recurrent high grade T1 urothelial carcinoma after completing therapy with at least induction BCG (>= 5 doses); patients with recurrent high grade T1 urothelial carcinoma after additional rounds of BCG will also be eligible, but one round of maintenance therapy or a second induction is not a pre-requisite for these patients. Trial registration must occur within 9 months of the last dose of BCG",
            "criterions": [
                {
                    "exact_snippets": "Patient has persistent or recurrent high grade T1 urothelial carcinoma",
                    "criterion": "high grade T1 urothelial carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "persistence or recurrence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "after completing therapy with at least induction BCG (>= 5 doses)",
                    "criterion": "induction BCG therapy",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number of doses",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "doses"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with recurrent high grade T1 urothelial carcinoma after additional rounds of BCG will also be eligible, but one round of maintenance therapy or a second induction is not a pre-requisite for these patients",
                    "criterion": "recurrent high grade T1 urothelial carcinoma after additional rounds of BCG",
                    "requirements": [
                        {
                            "requirement_type": "recurrence after additional BCG",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Trial registration must occur within 9 months of the last dose of BCG",
                    "criterion": "trial registration timing",
                    "requirements": [
                        {
                            "requirement_type": "time since last BCG dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 9,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2 x IULN (within 42 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) ... =< 2 x IULN",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "x IULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) ... =< 2 x IULN",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "x IULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have histologically proven, recurrent, non-muscle invasive urothelial carcinoma of the bladder within 60 days prior to registration; the carcinoma must be stage T1 high-grade, stage CIS, or stage Ta high-grade",
            "criterions": [
                {
                    "exact_snippets": "histologically proven",
                    "criterion": "urothelial carcinoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histology"
                        }
                    ]
                },
                {
                    "exact_snippets": "recurrent",
                    "criterion": "urothelial carcinoma recurrence",
                    "requirements": [
                        {
                            "requirement_type": "recurrence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "non-muscle invasive urothelial carcinoma of the bladder",
                    "criterion": "urothelial carcinoma type",
                    "requirements": [
                        {
                            "requirement_type": "muscle invasiveness",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": "bladder"
                        }
                    ]
                },
                {
                    "exact_snippets": "within 60 days prior to registration",
                    "criterion": "urothelial carcinoma diagnosis timing",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 60,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "stage T1 high-grade, stage CIS, or stage Ta high-grade",
                    "criterion": "urothelial carcinoma stage/grade",
                    "requirements": [
                        {
                            "requirement_type": "stage/grade",
                            "expected_value": [
                                "T1 high-grade",
                                "CIS",
                                "Ta high-grade"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be deemed unfit for radical cystectomy by the treating physician, or the patient must refuse radical cystectomy, which is considered standard of care for these patients; the reason for patients not to undergo cystectomy will be clearly documented",
            "criterions": [
                {
                    "exact_snippets": "Patients must be deemed unfit for radical cystectomy by the treating physician",
                    "criterion": "fitness for radical cystectomy",
                    "requirements": [
                        {
                            "requirement_type": "fitness",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "assessment_by_physician",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "the patient must refuse radical cystectomy",
                    "criterion": "refusal of radical cystectomy",
                    "requirements": [
                        {
                            "requirement_type": "refusal",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "the reason for patients not to undergo cystectomy will be clearly documented",
                    "criterion": "documentation of reason for not undergoing cystectomy",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have a baseline electrocardiograph (ECG) performed within 42 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "baseline electrocardiograph (ECG) performed within 42 days prior to registration",
                    "criterion": "electrocardiograph (ECG)",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 42,
                                "unit": "days prior to registration"
                            }
                        },
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (except Gilbert's syndrome, who must have a total bilirubin < 3.0 mg/dL) (within 42 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< 1.5 x institutional upper limit of normal (IULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x IULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except Gilbert's syndrome, who must have a total bilirubin < 3.0 mg/dL",
                    "criterion": "total bilirubin in patients with Gilbert's syndrome",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3.0,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "within 42 days prior to registration",
                    "criterion": "timing of total bilirubin measurement",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 42 days prior to registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No other prior malignancy is allowed except, for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years",
            "criterions": [
                {
                    "exact_snippets": "No other prior malignancy is allowed",
                    "criterion": "prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "except, for the following: adequately treated basal cell or squamous cell skin cancer",
                    "criterion": "basal cell or squamous cell skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "except, for the following: ... in situ cervical cancer",
                    "criterion": "in situ cervical cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "except, for the following: ... adequately treated stage I or II cancer from which the patient is currently in complete remission",
                    "criterion": "stage I or II cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        },
                        {
                            "requirement_type": "remission status",
                            "expected_value": "currently in complete remission"
                        }
                    ]
                },
                {
                    "exact_snippets": "except, for the following: ... any other cancer from which the patient has been disease free for five years",
                    "criterion": "any other cancer",
                    "requirements": [
                        {
                            "requirement_type": "disease free duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with mixed urothelial carcinoma and a glandular and/or squamous component will be eligible for the trial, but the presence of other histologic variants, pure adenocarcinoma, or pure squamous cell carcinoma, or pure squamous carcinoma in situ will make a patient ineligible",
            "criterions": [
                {
                    "exact_snippets": "mixed urothelial carcinoma and a glandular and/or squamous component will be eligible",
                    "criterion": "tumor histology",
                    "requirements": [
                        {
                            "requirement_type": "histologic subtype",
                            "expected_value": [
                                "mixed urothelial carcinoma with glandular component",
                                "mixed urothelial carcinoma with squamous component"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "presence of other histologic variants, pure adenocarcinoma, or pure squamous cell carcinoma, or pure squamous carcinoma in situ will make a patient ineligible",
                    "criterion": "tumor histology",
                    "requirements": [
                        {
                            "requirement_type": "histologic subtype",
                            "expected_value": {
                                "operator": "!=",
                                "value": 1,
                                "unit": "other histologic variants, pure adenocarcinoma, pure squamous cell carcinoma, pure squamous carcinoma in situ"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must not have had urothelial carcinoma in the prostatic urethra within the previous 24 months or muscle invasive urothelial carcinoma of the bladder at any time; patients with prior urothelial carcinoma in the upper urinary tract within the previous 24 months will only be eligible if they had =< T1 carcinoma and were treated with nephroureterectomy; patients must have a computed tomography (CT) or magnetic resonance imaging (MRI) (including CT-intravenous pyelogram [IVP], CT-urogram or MR-urogram) of the abdomen and pelvis to rule out upper tract malignancy and intra-abdominal metastases within 90 days prior to registration; if a patient cannot tolerate intravenous contrast, a retrograde pyelogram should be performed within 90 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "must not have had urothelial carcinoma in the prostatic urethra within the previous 24 months",
                    "criterion": "urothelial carcinoma in the prostatic urethra",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 24,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "muscle invasive urothelial carcinoma of the bladder at any time",
                    "criterion": "muscle invasive urothelial carcinoma of the bladder",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "prior urothelial carcinoma in the upper urinary tract within the previous 24 months ... only be eligible if they had =< T1 carcinoma and were treated with nephroureterectomy",
                    "criterion": "urothelial carcinoma in the upper urinary tract",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 24,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "T"
                            }
                        },
                        {
                            "requirement_type": "treatment",
                            "expected_value": "nephroureterectomy"
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a computed tomography (CT) or magnetic resonance imaging (MRI) (including CT-intravenous pyelogram [IVP], CT-urogram or MR-urogram) of the abdomen and pelvis to rule out upper tract malignancy and intra-abdominal metastases within 90 days prior to registration",
                    "criterion": "abdominal and pelvic imaging",
                    "requirements": [
                        {
                            "requirement_type": "modality",
                            "expected_value": [
                                "CT",
                                "MRI",
                                "CT-intravenous pyelogram",
                                "CT-urogram",
                                "MR-urogram"
                            ]
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 90,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": [
                                "rule out upper tract malignancy",
                                "rule out intra-abdominal metastases"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "if a patient cannot tolerate intravenous contrast, a retrograde pyelogram should be performed within 90 days prior to registration",
                    "criterion": "retrograde pyelogram",
                    "requirements": [
                        {
                            "requirement_type": "indication",
                            "expected_value": "cannot tolerate intravenous contrast"
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 90,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has persistent or recurrent high-grade Ta/CIS urothelial carcinoma after completing therapy with at least induction BCG (>= 5 doses) and first round maintenance (>= 2 doses) or second induction BCG (>= 2 doses); both rounds of BCG must have been administered within a 12 month period; these patients must have either had high-grade Ta tumors and did not achieve a disease-free state for more than 6 months following last dose of BCG, or they had CIS and did not achieve a CR; S1605 registration must occur within 9 months of the last dose of BCG",
            "criterions": [
                {
                    "exact_snippets": "persistent or recurrent high-grade Ta/CIS urothelial carcinoma",
                    "criterion": "urothelial carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "histology",
                            "expected_value": [
                                "high-grade Ta",
                                "CIS"
                            ]
                        },
                        {
                            "requirement_type": "disease_status",
                            "expected_value": [
                                "persistent",
                                "recurrent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "after completing therapy with at least induction BCG (>= 5 doses)",
                    "criterion": "induction BCG therapy",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dose_count",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "doses"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "first round maintenance (>= 2 doses) or second induction BCG (>= 2 doses)",
                    "criterion": "maintenance or second induction BCG therapy",
                    "requirements": [
                        {
                            "requirement_type": "dose_count",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "doses"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "both rounds of BCG must have been administered within a 12 month period",
                    "criterion": "BCG therapy rounds timing",
                    "requirements": [
                        {
                            "requirement_type": "administration_interval",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "high-grade Ta tumors and did not achieve a disease-free state for more than 6 months following last dose of BCG",
                    "criterion": "disease-free state after BCG in high-grade Ta tumors",
                    "requirements": [
                        {
                            "requirement_type": "disease_free_duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "CIS and did not achieve a CR",
                    "criterion": "complete response after BCG in CIS",
                    "requirements": [
                        {
                            "requirement_type": "complete_response",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "S1605 registration must occur within 9 months of the last dose of BCG",
                    "criterion": "registration timing",
                    "requirements": [
                        {
                            "requirement_type": "registration_interval",
                            "expected_value": {
                                "operator": "<=",
                                "value": 9,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have had all visible tumor resected completely within 60 days prior to registration; CIS disease is not expected to be completely excised; all patients must have tumor tissue from the histologic diagnosis of recurrence available for central pathology review submission; failure to submit these materials will make the patient ineligible for this study",
            "criterions": [
                {
                    "exact_snippets": "all visible tumor resected completely within 60 days prior to registration",
                    "criterion": "visible tumor resection",
                    "requirements": [
                        {
                            "requirement_type": "completeness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time_since_resection",
                            "expected_value": {
                                "operator": "<=",
                                "value": 60,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "tumor tissue from the histologic diagnosis of recurrence available for central pathology review submission",
                    "criterion": "tumor tissue from histologic diagnosis of recurrence",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "intended_use",
                            "expected_value": "central pathology review submission"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines",
            "criterions": [
                {
                    "exact_snippets": "Patients must be informed of the investigational nature of this study",
                    "criterion": "patient awareness of investigational nature",
                    "requirements": [
                        {
                            "requirement_type": "awareness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must sign and give written informed consent in accordance with institutional and federal guidelines",
                    "criterion": "written informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed and given",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "compliance with guidelines",
                            "expected_value": [
                                "institutional",
                                "federal"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests",
            "criterions": [
                {
                    "exact_snippets": "CD4 count above 250 cells/mcL",
                    "criterion": "CD4 count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 250,
                                "unit": "cells/mcL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "undetectable HIV viral load on standard PCR-based tests",
                    "criterion": "HIV viral load",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "test method",
                            "expected_value": "standard PCR-based tests"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If a patient does not meet these criteria only because the last dose of BCG was more than 9 months ago, the patient may become eligible if he/she shows histologically proven high-grade recurrence after an additional round of induction or maintenance BCG (>= 3 doses) within 9 months prior to registration",
            "criterions": [
                {
                    "exact_snippets": "histologically proven high-grade recurrence",
                    "criterion": "high-grade recurrence",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically proven"
                        }
                    ]
                },
                {
                    "exact_snippets": "an additional round of induction or maintenance BCG (>= 3 doses) within 9 months prior to registration",
                    "criterion": "BCG treatment",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "induction",
                                "maintenance"
                            ]
                        },
                        {
                            "requirement_type": "number of doses",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "doses"
                            }
                        },
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 9,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have had urine cytology within 21 days prior to registration; cytology for patients with CIS component is not expected to be negative for malignant cells; if the cytology for male patients with only Ta/T1 disease in the absence of CIS is positive for malignant cells, patient must have had a biopsy of the prostatic urethra within the previous six months",
            "criterions": [
                {
                    "exact_snippets": "Patients must have had urine cytology within 21 days prior to registration",
                    "criterion": "urine cytology",
                    "requirements": [
                        {
                            "requirement_type": "performed_within_days_prior_to_registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "cytology for patients with CIS component is not expected to be negative for malignant cells",
                    "criterion": "urine cytology result for patients with CIS component",
                    "requirements": [
                        {
                            "requirement_type": "malignant_cells_expected",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "if the cytology for male patients with only Ta/T1 disease in the absence of CIS is positive for malignant cells, patient must have had a biopsy of the prostatic urethra within the previous six months",
                    "criterion": "biopsy of the prostatic urethra for male patients with only Ta/T1 disease in the absence of CIS and positive cytology for malignant cells",
                    "requirements": [
                        {
                            "requirement_type": "performed_within_previous_months",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If a patient does not meet these criteria only because the last dose of BCG was more than 9 months ago, the patient may become eligible if he/she shows histologically proven high grade recurrence after an additional round of induction or maintenance BCG (>= 3 doses) within 9 months prior to registration",
            "criterions": [
                {
                    "exact_snippets": "histologically proven high grade recurrence",
                    "criterion": "high grade recurrence",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically proven"
                        }
                    ]
                },
                {
                    "exact_snippets": "an additional round of induction or maintenance BCG (>= 3 doses) within 9 months prior to registration",
                    "criterion": "BCG treatment",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "induction",
                                "maintenance"
                            ]
                        },
                        {
                            "requirement_type": "number of doses",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "doses"
                            }
                        },
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 9,
                                "unit": "months prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* As a part of the oncology patient enrollment network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system",
            "criterions": [
                {
                    "exact_snippets": "the treating institution's identity is provided",
                    "criterion": "treating institution identity",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "the current (within 365 days) date of institutional review board approval for this study has been entered in the system",
                    "criterion": "institutional review board approval date",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 365,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "entry_in_system",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have had cystoscopy confirming no visible papillary tumor within 21 days prior to registration; (CIS disease is not expected to have been completely excised); if the transurethral resection of bladder tumor (TURBT) or bladder biopsy falls within 21 days of registration it will fulfill this criterion",
            "criterions": [
                {
                    "exact_snippets": "cystoscopy confirming no visible papillary tumor within 21 days prior to registration",
                    "criterion": "visible papillary tumor on cystoscopy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time_window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "if the transurethral resection of bladder tumor (TURBT) or bladder biopsy falls within 21 days of registration it will fulfill this criterion",
                    "criterion": "TURBT or bladder biopsy",
                    "requirements": [
                        {
                            "requirement_type": "performed_within_time_window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All patients with T1 urothelial carcinoma at study entry must undergo re-TURBT within 60 days prior to registration, and must have evidence of uninvolved muscularis propria in the pathologic specimen from either the first or the second TURBT; tissue from the re-resection must be submitted for central review in addition to the tissue from the first TURBT; the TURBT that identified the recurrent T1 disease may have taken place more than 60 days prior to registration but not more than 120 days; patients with high grade Ta or CIS do not require a re-TURBT, but if this is performed at the discretion of the treating physician, the second TURBT must be within 60 days of registration; there is no requirement for muscularis propria in the specimen of Ta/CIS patients, but the tissue from the first and second TURBTs must be submitted for central review; if a patient with Ta/T1 disease undergoes repeat TURBT, the patient will be stratified as having CIS if there is CIS on either TURBT",
            "criterions": [
                {
                    "exact_snippets": "All patients with T1 urothelial carcinoma at study entry",
                    "criterion": "T1 urothelial carcinoma at study entry",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must undergo re-TURBT within 60 days prior to registration",
                    "criterion": "re-TURBT procedure",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 60,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must have evidence of uninvolved muscularis propria in the pathologic specimen from either the first or the second TURBT",
                    "criterion": "uninvolved muscularis propria in pathologic specimen",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "tissue from the re-resection must be submitted for central review in addition to the tissue from the first TURBT",
                    "criterion": "tissue submission for central review",
                    "requirements": [
                        {
                            "requirement_type": "specimens required",
                            "expected_value": [
                                "re-resection tissue",
                                "first TURBT tissue"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "the TURBT that identified the recurrent T1 disease may have taken place more than 60 days prior to registration but not more than 120 days",
                    "criterion": "timing of TURBT identifying recurrent T1 disease",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to registration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 60,
                                        "unit": "days prior to registration"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 120,
                                        "unit": "days prior to registration"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with high grade Ta or CIS do not require a re-TURBT, but if this is performed at the discretion of the treating physician, the second TURBT must be within 60 days of registration",
                    "criterion": "second TURBT for high grade Ta or CIS",
                    "requirements": [
                        {
                            "requirement_type": "requirement for re-TURBT",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "timing if performed",
                            "expected_value": {
                                "operator": "<=",
                                "value": 60,
                                "unit": "days of registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "there is no requirement for muscularis propria in the specimen of Ta/CIS patients",
                    "criterion": "muscularis propria in specimen for Ta/CIS patients",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "the tissue from the first and second TURBTs must be submitted for central review",
                    "criterion": "tissue submission for central review (Ta/CIS)",
                    "requirements": [
                        {
                            "requirement_type": "specimens required",
                            "expected_value": [
                                "first TURBT tissue",
                                "second TURBT tissue"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "if a patient with Ta/T1 disease undergoes repeat TURBT, the patient will be stratified as having CIS if there is CIS on either TURBT",
                    "criterion": "CIS on either TURBT (Ta/T1 disease)",
                    "requirements": [
                        {
                            "requirement_type": "stratification as CIS",
                            "expected_value": "if CIS present on either TURBT"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A stable regimen of highly active anti-retroviral therapy (HAART)",
            "criterions": [
                {
                    "exact_snippets": "A stable regimen of highly active anti-retroviral therapy (HAART)",
                    "criterion": "highly active anti-retroviral therapy (HAART) regimen",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient achieves disease-free state at 6 month time point (i.e., complete response; presence of only low-grade tumor at this timepoint is still considered complete response) after induction and maintenance (or second round of induction) BCG but later experiences a high-grade Ta/T1 recurrence (with or without concomitant CIS) within 6 months after the last dose of BCG or recurrent CIS (in absence of concomitant Ta/T1 tumor) within 12 months after the last BCG dose; the time of eligibility is measured from the last dose of BCG to the time of disease recurrence; the patient must be registered on the trial within 60 days of this recurrence, or within 60 days of a re-TURBT if indicated",
            "criterions": [
                {
                    "exact_snippets": "Patient achieves disease-free state at 6 month time point (i.e., complete response; presence of only low-grade tumor at this timepoint is still considered complete response) after induction and maintenance (or second round of induction) BCG",
                    "criterion": "disease-free state at 6 months after BCG",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": "complete response (including only low-grade tumor allowed)"
                        },
                        {
                            "requirement_type": "timepoint after BCG",
                            "expected_value": {
                                "operator": "=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "later experiences a high-grade Ta/T1 recurrence (with or without concomitant CIS) within 6 months after the last dose of BCG",
                    "criterion": "high-grade Ta/T1 recurrence after BCG",
                    "requirements": [
                        {
                            "requirement_type": "recurrence type",
                            "expected_value": "high-grade Ta/T1 (with or without CIS)"
                        },
                        {
                            "requirement_type": "time from last BCG dose to recurrence",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "or recurrent CIS (in absence of concomitant Ta/T1 tumor) within 12 months after the last BCG dose",
                    "criterion": "recurrent CIS after BCG",
                    "requirements": [
                        {
                            "requirement_type": "recurrence type",
                            "expected_value": "CIS (in absence of Ta/T1 tumor)"
                        },
                        {
                            "requirement_type": "time from last BCG dose to recurrence",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "the patient must be registered on the trial within 60 days of this recurrence, or within 60 days of a re-TURBT if indicated",
                    "criterion": "registration timing after recurrence or re-TURBT",
                    "requirements": [
                        {
                            "requirement_type": "time from recurrence or re-TURBT to registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 60,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have Zubrod performance status =< 2",
            "criterions": [
                {
                    "exact_snippets": "Zubrod performance status =< 2",
                    "criterion": "Zubrod performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All adverse events associated with any prior surgery and intravesical therapy must have resolved to grade =< 2 prior to registration",
            "criterions": [
                {
                    "exact_snippets": "All adverse events associated with any prior surgery and intravesical therapy must have resolved to grade =< 2 prior to registration",
                    "criterion": "adverse events from prior surgery and intravesical therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity grade",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) >= 1,500 microliter (mcL) (within 42 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 1,500 microliter (mcL)",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "microliter (mcL)"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets >= 100,000/mcL (within 42 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Platelets >= 100,000/mcL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mcL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be offered the opportunity to participate in specimen banking for future studies, to include translational medicine studies",
            "criterions": [
                {
                    "exact_snippets": "Patients must be offered the opportunity to participate in specimen banking for future studies, to include translational medicine studies",
                    "criterion": "opportunity to participate in specimen banking",
                    "requirements": [
                        {
                            "requirement_type": "offered",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine =< 1.5 ULN OR measured or calculated creatinine clearance >= 30 mL/min (within 42 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine =< 1.5 ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "measured or calculated creatinine clearance >= 30 mL/min (within 42 days prior to registration)",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 42 days prior to registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be BCG-unresponsive; a patient is BCG-unresponsive if they meet one or more of the following criteria:",
            "criterions": [
                {
                    "exact_snippets": "Patients must be BCG-unresponsive",
                    "criterion": "BCG-unresponsive status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections",
            "criterions": [
                {
                    "exact_snippets": "No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections",
                    "criterion": "requirement for concurrent antibiotics or antifungal agents for prevention of opportunistic infections",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patient must not have history of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis",
            "criterions": [
                {
                    "exact_snippets": "must not have history of idiopathic pulmonary fibrosis",
                    "criterion": "idiopathic pulmonary fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must not have history of ... pneumonitis (including drug induced)",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must not have history of ... organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.)",
                    "criterion": "organizing pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must not have ... evidence of active pneumonitis",
                    "criterion": "active pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "evidence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must not have active autoimmune disease that has required systemic treatment in past two years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment; autoimmune diseases include, but are not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis",
            "criterions": [
                {
                    "exact_snippets": "Patients must not have active autoimmune disease that has required systemic treatment in past two years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs)",
                    "criterion": "active autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "systemic treatment in past two years",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment",
                    "criterion": "replacement therapy for adrenal or pituitary insufficiency",
                    "requirements": [
                        {
                            "requirement_type": "systemic treatment classification",
                            "expected_value": "not considered systemic treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must not have active hepatitis B (chronic or acute) or active hepatitis C infection",
            "criterions": [
                {
                    "exact_snippets": "must not have active hepatitis B (chronic or acute)",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must not have ... active hepatitis C infection",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must not have an active infection requiring oral or IV antibiotics within 14 days prior to registration; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible",
            "criterions": [
                {
                    "exact_snippets": "must not have an active infection requiring oral or IV antibiotics within 14 days prior to registration",
                    "criterion": "active infection requiring oral or IV antibiotics",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 14,
                                        "unit": "days prior to registration"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible",
                    "criterion": "prophylactic antibiotic use",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible",
            "criterions": [
                {
                    "exact_snippets": "negative hepatitis B surface antigen [HBsAg] test",
                    "criterion": "hepatitis B surface antigen (HBsAg)",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "positive anti-HBc [antibody to hepatitis B core antigen] antibody test",
                    "criterion": "anti-HBc (antibody to hepatitis B core antigen) antibody",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the study",
            "criterions": [
                {
                    "exact_snippets": "Influenza vaccination should be given during influenza season only (approximately October to March)",
                    "criterion": "influenza vaccination",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "during influenza season only (approximately October to March)"
                        }
                    ]
                },
                {
                    "exact_snippets": "patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the study",
                    "criterion": "live, attenuated influenza vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "within 4 weeks prior to cycle 1, day 1",
                                "at any time during the study"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must not be planning to receive concomitant other biologic therapy, radiation therapy, intravesical chemotherapy, surgery, or other anti-cancer therapy while on this protocol",
            "criterions": [
                {
                    "exact_snippets": "must not be planning to receive concomitant other biologic therapy",
                    "criterion": "concomitant biologic therapy",
                    "requirements": [
                        {
                            "requirement_type": "planned receipt",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must not be planning to receive ... radiation therapy",
                    "criterion": "concomitant radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "planned receipt",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must not be planning to receive ... intravesical chemotherapy",
                    "criterion": "concomitant intravesical chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "planned receipt",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must not be planning to receive ... surgery",
                    "criterion": "concomitant surgery",
                    "requirements": [
                        {
                            "requirement_type": "planned receipt",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must not be planning to receive ... other anti-cancer therapy",
                    "criterion": "concomitant other anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "planned receipt",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must not have severe infections within 28 days prior to registration, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia",
            "criterions": [
                {
                    "exact_snippets": "Patients must not have severe infections within 28 days prior to registration",
                    "criterion": "severe infections",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "hospitalization for complications of infection",
                    "criterion": "hospitalization for complications of infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "bacteremia",
                    "criterion": "bacteremia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "severe pneumonia",
                    "criterion": "severe pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient must not have active tuberculosis",
            "criterions": [
                {
                    "exact_snippets": "must not have active tuberculosis",
                    "criterion": "active tuberculosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must not require treatment with a RANKL inhibitor (e.g. denosumab) who cannot discontinue it before treatment with atezolizumab",
            "criterions": [
                {
                    "exact_snippets": "Patients must not require treatment with a RANKL inhibitor (e.g. denosumab)",
                    "criterion": "requirement for RANKL inhibitor treatment",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "who cannot discontinue it before treatment with atezolizumab",
                    "criterion": "ability to discontinue RANKL inhibitor before atezolizumab",
                    "requirements": [
                        {
                            "requirement_type": "ability to discontinue",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must not have received treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 4 weeks prior to registration; exceptions: (1) patients may have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea); (2) the use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed",
            "criterions": [
                {
                    "exact_snippets": "must not have received treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 4 weeks prior to registration",
                    "criterion": "treatment with systemic immunosuppressive medications",
                    "requirements": [
                        {
                            "requirement_type": "exposure_within_timeframe",
                            "expected_value": {
                                "operator": "<",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "exposure",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must not have undergone prior allogeneic bone marrow transplantation or prior solid organ transplantation",
            "criterions": [
                {
                    "exact_snippets": "must not have undergone prior allogeneic bone marrow transplantation",
                    "criterion": "prior allogeneic bone marrow transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must not have undergone ... prior solid organ transplantation",
                    "criterion": "prior solid organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Due to the potential drug reaction with atezolizumab, patients must not be known to be allergic to Chinese hamster egg or ovaries",
            "criterions": [
                {
                    "exact_snippets": "patients must not be known to be allergic to Chinese hamster egg or ovaries",
                    "criterion": "allergy to Chinese hamster egg",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "patients must not be known to be allergic to Chinese hamster egg or ovaries",
                    "criterion": "allergy to Chinese hamster ovary",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must not have received a live, attenuated vaccine within 4 weeks before registration or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab",
            "criterions": [
                {
                    "exact_snippets": "must not have received a live, attenuated vaccine within 4 weeks before registration",
                    "criterion": "live, attenuated vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "administration status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab",
                    "criterion": "anticipated need for live, attenuated vaccine",
                    "requirements": [
                        {
                            "requirement_type": "anticipated administration period",
                            "expected_value": [
                                "during the study",
                                "up to 5 months after the last dose of atezolizumab"
                            ]
                        },
                        {
                            "requirement_type": "anticipated administration status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must not be pregnant or nursing due to the potential teratogenic side effects of the protocol treatment; administration of atezolizumab may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of study agent; a woman is considered to be of \"reproductive potential\" if she has had menses at any time in the preceding 12 consecutive months; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately",
            "criterions": [
                {
                    "exact_snippets": "Patients must not be pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients must not be ... nursing",
                    "criterion": "nursing status",
                    "requirements": [
                        {
                            "requirement_type": "nursing",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of study agent",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception method",
                            "expected_value": [
                                "hormonal",
                                "barrier",
                                "abstinence"
                            ]
                        },
                        {
                            "requirement_type": "contraception duration",
                            "expected_value": "prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose"
                        }
                    ]
                },
                {
                    "exact_snippets": "a woman is considered to be of \"reproductive potential\" if she has had menses at any time in the preceding 12 consecutive months",
                    "criterion": "reproductive potential (female)",
                    "requirements": [
                        {
                            "requirement_type": "menses in preceding 12 consecutive months",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must not have received any prior radiation to the bladder for bladder cancer",
            "criterions": [
                {
                    "exact_snippets": "must not have received any prior radiation to the bladder for bladder cancer",
                    "criterion": "prior radiation to the bladder for bladder cancer",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must not have had prior systemic chemotherapy for bladder cancer or systemic immunotherapy, including, but not limited to interferon alfa-2b, high dose interleukin 2 (IL-2), pegylated interferon (PEG-IFN), PD-1, anti-PD-L1, intra-tumoral; patients must not have had vaccine therapies within 6 weeks prior to registration; patients must not have received or be planning to receive any of the prohibited therapies during protocol treatment; prior intravesical administration of chemotherapy, interferon, Vicinium (VB4-485), BC-819 or Instiladrin (rAd-interferon-alpha/Syn3) is allowed if all other criteria are met and the last administration was >= 30 days before registration",
            "criterions": [
                {
                    "exact_snippets": "Patients must not have had prior systemic chemotherapy for bladder cancer",
                    "criterion": "prior systemic chemotherapy for bladder cancer",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "systemic immunotherapy, including, but not limited to interferon alfa-2b, high dose interleukin 2 (IL-2), pegylated interferon (PEG-IFN), PD-1, anti-PD-L1, intra-tumoral",
                    "criterion": "prior systemic immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "agents",
                            "expected_value": [
                                "interferon alfa-2b",
                                "high dose interleukin 2 (IL-2)",
                                "pegylated interferon (PEG-IFN)",
                                "PD-1",
                                "anti-PD-L1",
                                "intra-tumoral"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "patients must not have had vaccine therapies within 6 weeks prior to registration",
                    "criterion": "prior vaccine therapies",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "weeks prior to registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients must not have received or be planning to receive any of the prohibited therapies during protocol treatment",
                    "criterion": "prohibited therapies during protocol treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "planned treatment",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "prior intravesical administration of chemotherapy, interferon, Vicinium (VB4-485), BC-819 or Instiladrin (rAd-interferon-alpha/Syn3) is allowed if all other criteria are met and the last administration was >= 30 days before registration",
                    "criterion": "prior intravesical administration of chemotherapy, interferon, Vicinium (VB4-485), BC-819 or Instiladrin (rAd-interferon-alpha/Syn3)",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days before registration"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA",
            "criterions": [
                {
                    "exact_snippets": "Patients positive for hepatitis C virus (HCV) antibody",
                    "criterion": "hepatitis C virus (HCV) antibody",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "PCR is negative for HCV RNA",
                    "criterion": "HCV RNA by PCR",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}